VXRT - Vaxart stock jumps 12% after FDA clears IND for oral COVID-19 vaccine tablet

Vaxart (NASDAQ:VXRT) soars 11.8% premarket after announcing that the FDA has cleared its Investigational New Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate. "Together, the S-only and S+N constructs are part of our unique oral tablet COVID-19 vaccine candidate portfolio," said Andrei Floroiu, Vaxart's CEO. "Preliminary data from our current Non-Human Primate study indicates that the S-only vaccine produced much higher serum antibodies than the one expressing both S and N proteins," said Dr. Sean Tucker, Vaxart's Chief Scientific Officer. This new clinical trial will allow the company to compare the S-only and S+N vaccine candidates to decide which approach offers the best way forward for COVID-19 vaccine development program. In February 2021, Vaxart completed a Phase 1 trial for its oral S+N COVID-19 vaccine which suggested that the investigational oral vaccine triggered multiple immune responses against SARS-CoV-2 antigens, while reaching primary and secondary endpoints of safety and immunogenicity, respectively. The

For further details see:

Vaxart stock jumps 12% after FDA clears IND for oral COVID-19 vaccine tablet